Physician profile
Michael Seifu
NPI 1154717833
$1,941.51
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $137 · 2022: $191 · 2023: $1,290 · 2024: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,613.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $451.44 | 2022-2024 | Rexulti, Nuedexta, Abilify Asimtufii |
| Alkermes, INC. | $450.00 | 2022-2024 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $443.50 | 2021-2024 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $160.03 | 2023-2024 | Austedo Xr, Austedo, Uzedy |
| Ironshore Pharmaceuticals INC. | $69.55 | 2023-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $65.81 | 2023 | Auvelity |
| Tris Pharma INC | $61.39 | 2023 | Dyanavel Xr |
| Lundbeck LLC | $55.47 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.71 | 2021-2024 | Caplyta |
| Corium, LLC | $49.81 | 2023 | Azstarys |
| Noven Therapeutics, LLC | $24.57 | 2023 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $19.22 | 2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $13.47 | 2023 | Qelbree |
| Bioxcel Therapeutics, INC. | $13.26 | 2023 | Igalmi |
| Neuronetics, INC. | $9.28 | 2024 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Seifu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.